Note：

1. The clinical data were obtained from the package insert of Azvudine manufactured by Henan Sincere Biotechnology Co., Ltd..

2. The missing values in the primary efficacy outcome was imputed using a worst value method.

3. Clinical condition was determined according to the WHO Ordinary Clinical Progression Scale (Jun/2020), Score 4 to 10. The data was acquired according to the WHO score between day 1 and day 31.

4. The time to improvement in clinical condition was calculated in terms of the first time improvement in clinical condition emerged, which was determined by a decrease of ≥ 2 in the WHO score. The patients without any improvement in clinical condition by the end of the study were denoted as censoring patients. The last time that the WHO scare was determined was used to calculate the censoring time.